Business Context and Reporting Period
This Form 8-K Current Report was filed by Matinas Biopharma Holdings, Inc. (NYSE American: MTNB) on December 12, 2025. The filing reports on a corporate governance event involving the amendment of the Chief Executive Officer's employment agreement.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation terms and does not contain financial performance data.
Material Changes
The primary material change is the execution of the Third Amendment to the Employment Agreement between the Company and CEO Jerome D. Jabbour. Key modifications include:
- Retention Bonus Trigger Date: Extended from March 31, 2026, to June 30, 2026.
- Payment Structure: The Retention Bonus (greater of target annual bonus or $299,000) is now split: two-thirds payable upon execution of a definitive Change in Control agreement, and one-third payable immediately prior to closing.
- 2025 Annual Bonus: Guarantees Mr. Jabbour an annual bonus for the 2025 calendar year of no less than his target amount, payable by February 1, 2026, provided he remains employed without Cause or resignation without Good Reason.
- Definition Changes: "Change in Control" now includes transactions resulting in a material change to the Company's primary business. Definitions of "Cause" and "Good Reason" were also modified.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, financial outlook, or general risk factors. The primary contingency noted is the potential payment of the Retention Bonus, which is contingent upon a Change in Control occurring by June 30, 2026, or specific termination events (resignation for Good Reason or termination other than for Cause).
Investor Verification Checklist
- Verify the full text of the Third Amendment (Exhibit 10.1) to understand the specific definitions of "Cause" and "Good Reason."
- Confirm the CEO's current target annual bonus to calculate the potential Retention Bonus liability.
- Monitor for any announcements regarding a definitive agreement for a Change in Control before June 30, 2026.
- Review the Company's cash position to assess the ability to fund the guaranteed 2025 annual bonus and potential retention payments.